{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:39Z","timestamp":1786982379041,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s12325-020-01438-3","type":"journal-article","created":{"date-parts":[[2020,8,9]],"date-time":"2020-08-09T22:02:25Z","timestamp":1597010545000},"page":"4266-4279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Tiotropium\/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO\u00ae\/DYNAGITO\u00ae Trials"],"prefix":"10.1007","volume":"37","author":[{"given":"Jadwiga A.","family":"Wedzicha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Buhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus F.","family":"Vogelmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"de la Hoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Anzueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M. A.","family":"Calverley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,10]]},"reference":[{"key":"1438_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). 2019. https:\/\/goldcopd.org\/wp-content\/uploads\/2019\/11\/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed Feb 14, 2020."},{"issue":"47 suppl","key":"1438_CR2","doi-asserted-by":"publisher","first-page":"26s","DOI":"10.1183\/09031936.03.00030103","volume":"22","author":"P Calverley","year":"2003","unstructured":"Calverley P. Respiratory failure in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(47 suppl):26s\u201330s.","journal-title":"Eur Respir J"},{"issue":"1","key":"1438_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ccm.2013.11.001","volume":"35","author":"JA Wedzicha","year":"2014","unstructured":"Wedzicha JA, Singh R, Mackay AJ. Acute COPD exacerbations. Clin Chest Med. 2014;35(1):157\u201363.","journal-title":"Clin Chest Med"},{"issue":"10","key":"1438_CR4","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/thorax.57.10.847","volume":"57","author":"GC Donaldson","year":"2002","unstructured":"Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847\u201352.","journal-title":"Thorax"},{"issue":"5","key":"1438_CR5","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1164\/ajrccm.157.5.9709032","volume":"157","author":"TAR Seemungal","year":"1998","unstructured":"Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5):1418\u201322.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1438_CR6","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/2040622314532862","volume":"5","author":"H Qureshi","year":"2014","unstructured":"Qureshi H, Sharafkhaneh A, Hanania NA. Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. Ther Adv Chronic Dis. 2014;5(5):212\u201327.","journal-title":"Ther Adv Chronic Dis"},{"issue":"12","key":"1438_CR7","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","volume":"363","author":"JR Hurst","year":"2010","unstructured":"Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128\u201338.","journal-title":"N Engl J Med"},{"issue":"9","key":"1438_CR8","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1164\/rccm.202003-0625ST","volume":"201","author":"L Nici","year":"2020","unstructured":"Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of COPD: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56\u2013e69.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1438_CR9","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1183\/09031936.00136014","volume":"45","author":"R Buhl","year":"2015","unstructured":"Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2\u20134). Eur Respir J. 2015;45(4):969\u201379.","journal-title":"Eur Respir J"},{"issue":"8","key":"1438_CR10","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1164\/rccm.201706-1288OC","volume":"198","author":"T Troosters","year":"2018","unstructured":"Troosters T, Maltais F, Leidy N, et al. Effect of bronchodilation, exercise training, and behavior modification on symptoms and physical activity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(8):1021\u201332.","journal-title":"Am J Respir Crit Care Med"},{"key":"1438_CR11","doi-asserted-by":"publisher","unstructured":"Buhl R, Singh D, de la Hoz A, Xue W, Ferguson GT. Benefits of tiotropium\/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of the TONADO\u00ae and OTEMTO\u00ae studies. Adv Ther. 2020. https:\/\/doi.org\/10.1007\/s12325-020-01373-3.","DOI":"10.1007\/s12325-020-01373-3"},{"key":"1438_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01411-0","author":"R Buhl","year":"2020","unstructured":"Buhl R, de la Hoz A, Xue W, Singh D, Ferguson GT. Efficacy of tiotropium\/olodaterol compared with tiotropium as a first-line maintenance treatment in patients with COPD who are na\u00efve to LAMA, LABA and ICS: pooled analysis of four clinical trials. Adv Ther. 2020. https:\/\/doi.org\/10.1007\/s12325-020-01411-0.","journal-title":"Adv Ther"},{"issue":"5","key":"1438_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S2213-2600(18)30102-4","volume":"6","author":"PMA Calverley","year":"2018","unstructured":"Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6(5):337\u201344.","journal-title":"Lancet Respir Med"},{"issue":"23","key":"1438_CR14","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","volume":"374","author":"JA Wedzicha","year":"2016","unstructured":"Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222\u201334.","journal-title":"N Engl J Med"},{"issue":"3","key":"1438_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","volume":"1","author":"JA Wedzicha","year":"2013","unstructured":"Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199\u2013209.","journal-title":"Lancet Respir Med"},{"key":"1438_CR16","doi-asserted-by":"crossref","unstructured":"Suissa S. Improving the efficiency of randomized trials: the DYNAGITO example. COPD. 2019:1\u20133.","DOI":"10.1080\/15412555.2019.1698020"},{"issue":"18","key":"1438_CR17","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671\u201380.","journal-title":"N Engl J Med"},{"key":"1438_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.rmed.2018.08.012","volume":"143","author":"GT Ferguson","year":"2018","unstructured":"Ferguson GT, Buhl R, Bothner U, et al. Safety of tiotropium\/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials. Respir Med. 2018;143:67\u201373.","journal-title":"Respir Med"},{"issue":"1","key":"1438_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41533-016-0002-x","volume":"27","author":"GT Ferguson","year":"2017","unstructured":"Ferguson GT, Karpel J, Bennett N, et al. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies. NPJ Prim Care Respir Med. 2017;27(1):7.","journal-title":"NPJ Prim Care Respir Med"},{"issue":"10","key":"1438_CR20","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.rmed.2015.08.002","volume":"109","author":"D Singh","year":"2015","unstructured":"Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109(10):1312\u20139.","journal-title":"Respir Med"},{"issue":"5","key":"1438_CR21","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1378\/chest.13-1579","volume":"145","author":"B Celli","year":"2014","unstructured":"Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium\/vilanterol 125\/25 mcg in COPD: a randomized, controlled study. Chest. 2014;145(5):981\u201391.","journal-title":"Chest"},{"key":"1438_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.rmed.2017.02.008","volume":"125","author":"A D'Urzo","year":"2017","unstructured":"D'Urzo A, Rennard S, Kerwin E, et al. A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium\/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respir Med. 2017;125:39\u201348.","journal-title":"Respir Med"},{"issue":"1","key":"1438_CR23","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/1471-2466-14-178","volume":"14","author":"D Singh","year":"2014","unstructured":"Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide\/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14(1):178.","journal-title":"BMC Pulm Med"},{"issue":"10","key":"1438_CR24","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.rmed.2013.06.001","volume":"107","author":"JF Donohue","year":"2013","unstructured":"Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium\/vilanterol 62.5\/25 mcg in COPD. Respir Med. 2013;107(10):1538\u201346.","journal-title":"Respir Med"},{"issue":"11","key":"1438_CR25","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.rmed.2008.07.020","volume":"102","author":"C Vogelmeier","year":"2008","unstructured":"Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono-and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008;102(11):1511\u201320.","journal-title":"Respir Med"},{"key":"1438_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.rmed.2017.03.015","volume":"126","author":"NA Hanania","year":"2017","unstructured":"Hanania NA, Tashkin DP, Kerwin EM, et al. Long-term safety and efficacy of glycopyrrolate\/formoterol metered dose inhaler using novel Co-Suspension\u2122 Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017;126:105\u201315.","journal-title":"Respir Med"},{"key":"1438_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.rmed.2016.05.007","volume":"116","author":"JF Donohue","year":"2016","unstructured":"Donohue JF, Soong W, Wu X, Shrestha P, Lei A. Long-term safety of aclidinium bromide\/formoterol fumarate fixed-dose combination: results of a randomized 1-year trial in patients with COPD. Respir Med. 2016;116:41\u20138.","journal-title":"Respir Med"},{"issue":"4","key":"1438_CR28","first-page":"716","volume":"3","author":"GT Ferguson","year":"2016","unstructured":"Ferguson GT, Taylor AF, Thach C, et al. Long-term maintenance bronchodilation with indacaterol\/glycopyrrolate versus indacaterol in moderate-to-severe COPD patients: the FLIGHT 3 study. Chronic Obstr Pulm Dis. 2016;3(4):716.","journal-title":"Chronic Obstr Pulm Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01438-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01438-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01438-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T19:54:19Z","timestamp":1628538859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01438-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1438"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01438-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,10]]},"assertion":[{"value":"20 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}